Schering-Plough Announces Global Agreement With Novartis to Develop Once-Daily Combination Therapy for Asthma and COPD Aug 14, 2006
Today, NASONEX (mometasone furoate monohydrate) and the CLARINEX (desloratadine) family of nonsedating prescription antihistamines (marketed in Europe under the trade names AERIUS(TM) and NEOCLARITYN(TM)) provide physicians and patients with a variety of treatment options. Schering-Plough continues to make available in the U.S. FORADIL AEROLIZER, a long-acting beta2 agonist for asthma and chronic obstructive pulmonary disease. (PR Newswire)
CIMA LABS' OraSolv(R) Technology Used in CLARINEX(R) (desloratadine) Reditabs(R) Re-formulation Aug 26, 2005
Aug. 25 /PRNewswire-FirstCall/ -- CIMA LABS INC., a Cephalon company (Nasdaq: - ), announced today that Schering-Plough Corporation plans to market an orally disintegrating version of CLARINEX (desloratadine), its prescription antihistamine product using OraSolv, a proprietary orally disintegrating drug delivery technology developed by CIMA LABS.. ADVERTISEMENT. (Yahoo Finance -- Biotechnology & Drugs)
Schering-Plough Plans Tutti-Frutti Clarinex Jul 16, 2005
5 milligrams and 5 milligrams of desloratadine. Schering-Plough said the new formulation will be available in pharmacies in September and will come in a new "tutti frutti" flavor. (Yahoo Finance -- Major Drugs)
FDA Approves Re-Formulated CLARINEX(R) (desloratadine) REDITABS(R) Tablets - Orally Disintegrating Prescription Antihistamine Jul 16, 2005
KENILWORTH, N.J., July 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: - ) today announced that the U.S. Food and Drug Administration (FDA) has approved re-formulated CLARINEX (desloratadine 2 ... 5 mg per 1 mL) Syrup for children as young as 6 months old, CLARINEX REDITABS for both adults and children starting at 6 years of age and CLARINEX (5 mg) Tablets and CLARINEX-D 24 HOUR (desloratadine 5 mg/pseudoephedrine 240 mg) Extended Release Tablets for patients 12 years of age... (Yahoo Finance -- Major Drugs)
NASONEX(R) (mometasone furoate monohydrate) Effective for Nasal Polyps with Once-Daily Dose Jun 29, 2005
Products from the company's research efforts include the CLARITIN (loratadine) family of nonsedating antihistamines, CLARINEX (desloratadine) syrup and tablets and CLARINEX-D 24 Hour (desloratadine 5mg and pseudoephedrine sulfate USP 240 mg) Extended Release Tablets. Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. (Yahoo Finance -- Major Drugs)
Allergies: The new anti-aphrodisiac Mar 30, 2005
A recent head-to head clinical study (A. Purohit et al. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Annals of Allergy, Asthma and Immun, June 2004) comparing the efficacy of Reactine's cetirizine versus desloratadine (the medicinal ingredient found in Aerius, an evolution of Claritin) suggests that cetirizine reached efficacy faster (0. (Canada Newswire)
Allergies in October?? Oct 14, 2004
Drug interaction studies also showed no interactions with ketoconazole or erythromycin, grapefruit juice or antacids, some of which have occurred with other antihistamines, such as those with the medicinal ingredients loratadine, desloratadine and fexofenadine. This is important, particularly as overmedicating/drug interactions are key concerns for sufferers. (Canada Newswire)
WED Sep 1, 04, 5:30 PM Sep 2, 2004
FDA Approves CLARINEX(R) (Desloratadine) Syrup for Relief of Symptoms Associated With Indoor and Outdoor Allergies and Hives in Children ... FDA Approves CLARINEX(R) (Desloratadine) Syrup for Relief of Symptoms Associated With Indoor and Outdoor Allergies and Hives in Children ... -- Indoor Allergies and Hives for Children Six Months and Older -- Outdoor Allergies for Children Two Years and Older KENILWORTH, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) announced... (PR Newswire)
Sepracor Announces First Quarter 2004 Operating Results Apr 27, 2004
CLARINEX(R) brand desloratadine - Sepracor earns royalties from Schering- Plough Corporation on sales of all formulations of CLARINEX brand desloratadine in the U.S. and in other countries where Sepracor holds patents relating to desloratadine. CLARINEX is indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria (CIU), also known as hives of unknown cause, in patients 12 years of age and older. (PR Newswire)
Schering Canada Inc. - Latest Advance in Allergy Treatments Now Available Over-the-Counter Mar 20, 2004
Search by Organization. 2003 Canada NewsWire Ltd.. (Canada Newswire)
